KPMG Video Insights

Venture Champion Final - June 10th, 2024

Tue, 18 Jun 2024 14:30:11 GMT

As part of the KPMG Global Tech Innovator Awards, KPMG Venture Services is organising the Venture Champion Award for the second time this summer. Selected investors each nominate three start-ups from their field. From the field of all nominated and registered start-ups, first all investors and then all invited networkers (experts in the scene) vote to determine the first nine finalists.
The tenth and final place for the final will be awarded as a wildcard to the start-up that can mobilise the most advocates in the ecosystem (ecosystem wildcard).

The evening event on 10 June in Berlin with pitch competition, award ceremony and networking is the exclusive highlight for all invited guests and brings together founders, investors, networkers and representatives of well-known companies. The winner of the Venture Champion will travel to Lisbon as part of the WebSummit and represent the German start-up ecosystem at the Global Tech Innovator.

Further information about participation requirements, evaluation criteria and more can be found under https://atlas.kpmg.com/de/de/kpmg-venture-champion

Trends and challenges for life sciences companies in the new reality

Tue, 05 Jan 2021 17:38:10 GMT

Life sciences companies have maneuvered quite well through the Covid-19 pandemic. In the new reality it will be relevant, that the companies leverage their increased societal importance to develop innovative drugs at affordable prices and to become more customer-oriented. Thomas Hillek, Head of Life Sciences & Chemicals at KPMG in Germany, explains which four overarching trends influence the new reality of life sciences companies and highlights possible actions.

M&A market and life sciences companies: transactions in the new reality

Tue, 05 Jan 2021 16:57:56 GMT

The global M&A market declined significantly during the Covid-19 pandemic. This has also been reflected in transactions in the life sciences sector. However, our expert Christian Klingbeil assumes that the transaction market will recover quite quickly – first acquisitions can already be observed again. In this video, he explains how the transaction strategy of life sciences companies looks like in the new reality.

Digitalization of life sciences companies in the new reality

Tue, 05 Jan 2021 16:47:48 GMT

Adapting to changing customer expectations, reducing the time to market for products and therapies and managing digital channels: these are the three major challenges for life sciences companies in the new reality our expert Ashish Madan (https://home.kpmg/de/en/home/contacts/m/ashish-madan.html) defines. The digital transformation plays an outstanding role in coping with these tasks and Ashish Madan explains which topics companies should focus on in this context and gives recommendations for action.

Tax implications for life sciences companies due to Covid-19

Tue, 05 Jan 2021 16:27:24 GMT

In many life sciences companies the corona pandemic has triggered developments with tax implications: for example, accelerated digitalization and re-nationalization of supply chains. Our expert Dr. Kai Reusch explains why tax authorities in many countries are interested in digital business models and how a relocation of supply chains affects the transfer pricing system and indirect tax position.

Cyber Security and life sciences companies: new threats from Covid-19

Tue, 05 Jan 2021 16:09:23 GMT

The corona crisis and its associated measures have accelerated digitization in many companies – including life sciences companies. This has led to new attack scenarios for cybercrime. Even if there is no such thing as 100 percent security, as our expert Marko Vogel says, companies can do a lot to protect themselves against cyberattacks. Marko Vogel explains in the video which activities companies have to address in this context and which considerations they should take into account when it comes to cyber security.